Proton pump inhibitors (PPIs) have been proposed to be effective in eosinophilic esophagitis not only for symptomatic relief by reducing the acidity of gastric juice, but it is found to inhibit IL‐4 stimulated eotaxin‐3 expression by blocking the gene promoter resulting in clinical, endoscopic, and histologic improvement in a certain population [55, 56]. This evidence concerns the gene CCL26 and eosinophilic esophagitis.